Luay Darwish Holding LLC
Prof. Chen collaborated with PharmaEngine for the development of PEP02 since 2004. He is the director of National Institute of Cancer Research, National Health Research Institutes, Taiwan and Professor of National Cheng Kung University and Kaohsiung Medical University, Taiwan. As s a board certified gastroenterologist and medical oncologist, he focuses on the development of innovative strategies for treating prevalent gastrointestinal tract (including, hepatobiliary and pancreas) cancers in Taiwan, through conducting clinical trials and trial-related translational research. He was the key investigator in the NAPOLI-1 phase III study, which resulted in the approval of PEP02/MM-398 for the patients with gemcitabine-treated metastatic pancreatic cancer. He received his M.D. and Ph.D. from Kaohsiung Medical University, Taiwan.